Stifel initiated coverage of Tango Therapeutics (TNGX) with a Buy rating and $15 price target The firm views the company’s vopimetostat as a potential “best-in-class” PRMT5 inhibitor. The drug could become the standard of care in in second-line MTAP-deleted pancreatic ductal adenocarcinoma, the analyst tells investors in a research note. Stifel sees peak global revenue of $1.2B by 2035.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics Enters New Sales Agreement with Leerink
- Tango Therapeutics files to sell 1.73M shares of common stock for holders
- Tango Therapeutics files automatic mixed securities shelf
- Perspective Therapeutics price target lowered to $11 from $12 at B. Riley
- Tango Therapeutics price target raised to $14 from $8 at B. Riley